ALSO NOTED: Trisenox demonstrates survival benefits; Cytori shares rise on FDA approval; and much more...

> A new study of Cephalon's Trisenox for acute promyelocytic leukemia demonstrated increased survival time. "The results of this study showing a survival benefit associated with the use of Trisenox in patients with APL are an important development for physicians and patients, as demonstrated by the urgency to disseminate the results to clinicians in an expedited manner," says Dr. Lesley Russell, executive vice president of Cephalon. "We are encouraged by the oncology community's continued interest in the potential of Trisenox, and these study results reinforce Cephalon's commitment to build a fully integrated oncology business." Release

> Shares of Cytori Therapeutics, a stem cell company, got a bump this morning after it announced that the FDA had approved its fat tissue processing system. Report

> The death of a Russian dissident from radiation poison has focused new attention on Ovation Pharmaceuticals Chemet, which treats the symptoms of exposure to radiation. The company says the fresh attention could translate into federal funding. Article

> An EU expert panel has backed approval of Januvia and Xelevia for diabetes as well as the extended use of prevenar and xyrem. Report

> Gentris has received FDA approval for one of its genomics tests. Report

> Resverlogix has retained UBS Securities advise the company on an evaluation of "strategic alternatives." Release

> DOV Pharmaceutical has restructured its debt, exchanging $70 million in debentures for shares and $14.9 million in cash. Release

> Oculus Innovative Sciences has priced its IPO at $8 a share. Release

> Reactivated p53 gene plays role in fighting tumors. Report

> Autoimmune disease research points to new therapies. Report

> Alzheimer's patch used to deliver vaccine to mice. Report

And Finally… British scientists are using robotics to automate stem cell research and quicken the speed of the discovery process. Release